Back to search

Peptide record

TPDB09031

Antibacterial Anticancer Antifungal Toxicity standard
19 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09031
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia Antifungipept
standard
No
A 19-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, and Antifungipept, with an available 3D structural model.
Sequence
LPRRNRWSKIWKKVVTVFS
Physicochemical Analysis
C113H182N34O24
ADCEQGHMY
RKV
2400.90
12.71
6
0
8
+6
1.18
-0.563
86.84
Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min
11000
458.16
4
Residue Composition
number
0
A
3
R
1
N
0
D
0
C
0
E
0
Q
0
G
0
H
1
I
1
L
3
K
0
M
1
F
1
P
2
S
1
T
2
W
0
Y
3
V
Amino Acid Distribution
A: 0 R: 3 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 1 K: 3 M: 0 F: 1 P: 1 S: 2 T: 1 W: 2 Y: 0 V: 3
Chemical Descriptors
19
C113H182N34O24
2400.90
12.71
+6
1.18
-0.563
Evidence Records 19 records
Evidence 1 Activity

Activity

MIC
Antibacterial
8-32 µg/mL

Target

Staphylococcus aureus

Source & Reference

NA

Other

Active against bacteria S. aureus(MIC 8-32 ug/ml), K. pneumoniae (MIC 16-32 ug/ml), A. baumannii and 14 clinical strains (MIC 4-16 ug/ml),
Evidence 2 Activity

Activity

MIC
Antibacterial
16-32 µg/mL

Target

Klebsiella pneumoniae

Source & Reference

NA

Other

Active against bacteria S. aureus(MIC 8-32 ug/ml), K. pneumoniae (MIC 16-32 ug/ml), A. baumannii and 14 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (16-64 ug/ml), C. j
Evidence 3 Activity

Activity

MIC
Antibacterial
4-16 µg/mL

Target

A. baumannii and 14 clinical strains

Source & Reference

NA

Other

Active against bacteria S. aureus(MIC 8-32 ug/ml), K. pneumoniae (MIC 16-32 ug/ml), A. baumannii and 14 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (16-64 ug/ml), C. jejuni (4-64 ug/ml), E. coli K12 (MIC 32 ug/ml), S. typh
Evidence 4 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

Escherichia coli K12

Source & Reference

NA

Other

4 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (16-64 ug/ml), C. jejuni (4-64 ug/ml), E. coli K12 (MIC 32 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 u
Evidence 5 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

S. typhimurium

Source & Reference

NA

Other

ug/ml), P. aeruginosa (16-64 ug/ml), C. jejuni (4-64 ug/ml), E. coli K12 (MIC 32 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: in
Evidence 6 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

Enterococcus faecalis

Source & Reference

NA

Other

g/ml), C. jejuni (4-64 ug/ml), E. coli K12 (MIC 32 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: inhibited bacterial biofilm fo
Evidence 7 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

L. monocytogenes

Source & Reference

NA

Other

E. coli K12 (MIC 32 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: inhibited bacterial biofilm formation and disrupted bacterial biof
Evidence 8 Activity

Activity

MIC
Antifungal
8-32 µg/mL

Target

Staphylococcus aureus

Source & Reference

Antifungipept

Other

Active against bacteria S. aureus(MIC 8-32 ug/ml), K. pneumoniae (MIC 16-32 ug/ml), A. baumannii and 14 clinical strains (MIC 4-16 ug/ml),
Evidence 9 Activity

Activity

MIC
Antifungal
16-32 µg/mL

Target

Klebsiella pneumoniae

Source & Reference

Antifungipept

Other

Active against bacteria S. aureus(MIC 8-32 ug/ml), K. pneumoniae (MIC 16-32 ug/ml), A. baumannii and 14 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (16-64 ug/ml), C. j
Evidence 10 Activity

Activity

MIC
Antifungal
4-16 µg/mL

Target

A. baumannii and 14 clinical strains

Source & Reference

Antifungipept

Other

Active against bacteria S. aureus(MIC 8-32 ug/ml), K. pneumoniae (MIC 16-32 ug/ml), A. baumannii and 14 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (16-64 ug/ml), C. jejuni (4-64 ug/ml), E. coli K12 (MIC 32 ug/ml), S. typh
Evidence 11 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

Escherichia coli K12

Source & Reference

Antifungipept

Other

4 clinical strains (MIC 4-16 ug/ml), P. aeruginosa (16-64 ug/ml), C. jejuni (4-64 ug/ml), E. coli K12 (MIC 32 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 u
Evidence 12 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

S. typhimurium

Source & Reference

Antifungipept

Other

ug/ml), P. aeruginosa (16-64 ug/ml), C. jejuni (4-64 ug/ml), E. coli K12 (MIC 32 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: in
Evidence 13 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

Enterococcus faecalis

Source & Reference

Antifungipept

Other

g/ml), C. jejuni (4-64 ug/ml), E. coli K12 (MIC 32 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: inhibited bacterial biofilm fo
Evidence 14 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

L. monocytogenes

Source & Reference

Antifungipept

Other

E. coli K12 (MIC 32 ug/ml), S. typhimurium (MIC 32 ug/ml), E. faecalis (MIC 32 ug/ml) and L. monocytogenes (MIC 32 ug/ml). Antibiofilm:bacteria: inhibited bacterial biofilm formation and disrupted bacterial biof
Evidence 15 Activity

Activity

20% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
20% Hemolysis | 500 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The rumen microbiome: an underexplored resource for novel antimicrobial discovery. | NPJ Biofilms Microbiomes | 2017
Evidence 16 Activity

Activity

10% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 500 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
The rumen microbiome: an underexplored resource for novel antimicrobial discovery. | NPJ Biofilms Microbiomes | 2017
Evidence 17 Activity

Activity

LC50
Toxicity
98.1 µg/mL
Cytotoxic
LC50 | 98.1 | µg/mL | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
The rumen microbiome: an underexplored resource for novel antimicrobial discovery. | NPJ Biofilms Microbiomes | 2017
Evidence 18 Activity

Activity

0% Hemolysis
Toxicity
536 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 536 | µg/mL | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Molecular Basis of Selectivity and Activity for the Antimicrobial Peptide Lynronne-1 Informs Rational Design of Peptide with Improved Activity. | Chembiochem | 2021
Evidence 19 Activity

Activity

LC50
Toxicity
98.1 µg/mL
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: 20% Hemolysis=500µg/ml Sheep erythrocytes: 10% Hemolysis=500µg/ml Horse erythrocytes:0% Hemolysis=536µg/ml | Cytotoxicity: HUVEC: LC50=98.1µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
NPJ Biofilms Microbiomes. 2017 Dec 1 3:33.